Trace Elements 4
Drug
American Regent
Total Payments
$87,982
Transactions
6
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $81,022 | 4 | 2 |
| 2021 | $6,960 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75,898 | 4 | 86.3% |
| Consulting Fee | $12,084 | 2 | 13.7% |
Payments by Type
Research
$75,898
4 transactions
General
$12,084
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Anemia Treatment Patterns and Outcomes among a National Cohort of Patients with Inflammatory Bowel Disease | American Regent | $48,903 | 0 |
| TE20002 | American Regent | $20,035 | 0 |
| TRALEMENT TE20001/TE20002 | American Regent | $6,960 | 1 |
Ad
Manufacturing Companies
- American Regent $87,982
Product Information
- Type Drug
- Total Payments $87,982
- Total Doctors 3
- Transactions 6
About Trace Elements 4
Trace Elements 4 is a drug associated with $87,982 in payments to 3 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is American Regent.
Payment data is available from 2021 to 2024. In 2024, $81,022 was paid across 4 transactions to 2 doctors.
The most common payment nature for Trace Elements 4 is "Unspecified" ($75,898, 86.3% of total).
Trace Elements 4 is associated with 3 research studies, including "Anemia Treatment Patterns and Outcomes among a National Cohort of Patients with Inflammatory Bowel Disease" ($48,903).